Đang chuẩn bị liên kết để tải về tài liệu:
Response to post-axitinib treatment in patients with metastatic renal cell carcinoma

Không đóng trình duyệt đến khi xuất hiện nút TẢI XUỐNG

Axitinib is a potent inhibitor of the vascular endothelial growth factor (VEGF) receptor family with clinical activity in patients with metastatic renal cell carcinoma (mRCC). Given this biochemical potency, the clinical activity of subsequent treatment with targeted therapies in patients progressing on axitinib is of interest. |

TÀI LIỆU LIÊN QUAN

Community Response to Road Traffic Noise in Hue City, Vietnam

Lecture Control system design: Frequency response methods - Nguyễn Công Phương

Optimization of conditions for extraction of collagen from the skin of Pangasius hypophthalmus by response surface methodology

Soil test crop response based fertilizer prescription for urd grown on Mollisol of Uttarakhand, India

Optimization of alcoholic fermentation of custard apple juice by Saccharomyces cerevisiae using response surface methodology

Reducing ambulance response time in emergency medical services: A literature review

Lecture Introduction to Circuits for ECE - Lesson 19: Step response and impulse response

Personal-response approach vs reader-response approach in literature-based English language teaching

Pretreatment systemic inflammation response index is predictive of pathological complete response in patients with breast cancer receiving neoadjuvant chemotherapy

A comparison of effects of scalp nerve block and local anesthetic infiltration on inflammatory response, hemodynamic response, and postoperative pain in patients undergoing craniotomy for cerebral aneurysms: A randomized controlled trial
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.